Artiria Medical SA raises USD 6m in a Series A2 Financing Round

1 March 2024

Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation neuro-interventional products for stroke and aneurysms, closed a USD 6m series A2 financing round. The round was led by 4FOX Ventures, with the Wyss Center for Bio and Neuroengineering joining several of the company's existing investors. The funds will be used to advance clinical studies in stroke in Europe and the U.S.

The VISCHER team advising Artiria Medical SA in this transaction included Matthias Staehelin (Partner, Corporate/M&A) and Vincent S. Reardon (Managing Associate, Corporate/M&A).

Authors: Matthias Staehelin and Vincent S. Reardon